Friday, July 10, 2026

Drug profile · INN

kn046

kn046 is a cytotoxic t-lymphocyte protein 4 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 1
Drug details — kn046

Quick answer

kn046 is a cytotoxic t-lymphocyte protein 4 inhibitor.

Key facts

INN kn046
Mechanism Cytotoxic T-lymphocyte protein 4 inhibitor
Target Cytotoxic T-lymphocyte protein 4

Mechanism of action

Cytotoxic T-lymphocyte protein 4 inhibitor

Primary target: Cytotoxic T-lymphocyte protein 4

Approval history

Authority Status Date
NMPA clinical trials

Recent coverage

Pipeline programs

  1. KN046 Phase 2 · Jiangsu Alphamab Biopharmaceuticals · Esophageal Squamous Cell Carcinoma
  2. KN046 Phase 2 · First People's Hospital · Esophageal Squamous Cell Carcinoma
  3. KN046 (PD-L1/CTLA4 BsAb) Phase 2 · Sunshine Guojian Pharmaceutical · Advanced HCC

Related & competitor drugs

  1. ipilimumab Antineoplastic and immunomodulating agents (L01)
  2. tremelimumab-actl Cytotoxic T-lymphocyte protein 4 inhibitor
  3. tremelimumab Antineoplastic and immunomodulating agents (L01)
  4. ak104 Cytotoxic T-lymphocyte protein 4 inhibitor
  5. cadonilimab Cytotoxic T-lymphocyte protein 4 inhibitor

Frequently asked questions

What is kn046?

kn046 is a cytotoxic t-lymphocyte protein 4 inhibitor.